Objective : Cardiovascular function assessment is most often a mandatory requirement in preclinical studies in all industrialized countries. The invasiveness and impact of the monitoring devices used on animals have to be reduced as far as possible for scientific as well as ethical reasons. In humans, inductive plethysmography (IP) is a commonly used wearable non-invasive technology based on volume recordings. The innovative target of the present work is to transfer the IP technology to cardiac output (CO) measurement in rodents. Approach : A new IP device specifically designed for rodents was developed and compared with the gold standard equipment for CO assessment in rodents. CO was monitored in anesthetized rats equipped with both the IP device and an ultrasonic flow probe during a hemodynamic challenge (volume overload). Main results : Cardiac blood flow measurements with the new IP device are significantly correlated with those obtained with the ultrasonic probe throughout the volume overload procedure ( r = 0.97, p < 0.001). Significance : Our results clearly show that the IP device has adequate technological characteristics to allow accurate CO measurement and can therefore be used for longitudinal non-invasive monitoring in rats.
The development of alternative methods for monitoring cardiorespiratory function without restraint or surgical implantation is attracting growing interest for both ethical and scientific reasons. For this purpose, a new non-invasive jacketed telemetry tool consisting in a radio device maintained in a jacket worn by the animal was previously developed to improve cardiorespiratory monitoring. It allows simultaneous monitoring of cardiac activity by surface electrocardiagram, respiratory function by respiratory inductive plethysmography, and locomotor activity by accelerometry. However, this tool has only been validated under conditions of low/intermediate activity levels or in anesthetized animals. This study aimed to evaluate the feasibility of using this system in the challenging conditions of an exertion protocol. Male Wistar rats ( n = 10, 8–9 weeks old) were subjected to an incremental treadmill exercise protocol including speed levels from 5 to 40 cm s −1 separated by 30-s breaks. Heart rate (HR) and minute ventilation (assessed by minute volume; MV) were continuously monitored. At the end of each running level and during the 30-s breaks, HR and MV showed a significant increase compared to resting values. They returned to the baseline within 60 min of post-exercise recovery. Overall, our results demonstrated (i) the ability of the animal to run while wearing the device and (ii) the ability of the device to reliably monitor cardiorespiratory adaptation to treadmill exercise despite significant mechanical disturbances. In conclusion, this study highlights the possibility of non-invasively monitoring cardiorespiratory functional variables that were previously unattainable under conditions of high activity in freely moving animals.
Objective: Hemodynamic monitoring is essential in preclinical research. Currently available techniques are either invasive or complex to implement. Inductive plethysmography (IP) provides an alternative for estimating stroke volume and cardiac output, as the IP signal includes ventilatory and cardiogenic oscillations (COS). COS monitoring, also defined as thoracocardiography (TCG), has been validated in humans and large laboratory animals. A recent study demonstrated proof of concept in COS extraction from the TCG signal recorded during respiratory pauses in mechanically-ventilated laboratory rats using a high-resolution IP device. The present study aims to develop an ensemble averaging (EA) algorithm, triggered by the electrocardiogram (ECG) R-peak, to extract COS from TCG signals in rats and continuously estimate stroke volume and cardiac output. Approach: After an evaluation of the IP device using the EA technique on a mechanical test bench, the applicability of the EA technique was tested in anesthetized rats without ventilatory support during a pharmacological challenge. The ability of the algorithm to track stroke volume and cardiac output changes during the hemodynamic test was also evaluated. Main Results: Metrological evaluation of the IP device using the EA technique demonstrated linearity across the physiological operating range and resolution sufficient to detect volume changes of less than 10% of typical physiological values. Although the assumptions underlying the use of EA cannot be fully satisfied for COS extraction—due to quasi-synchrony with the ECG R-peak and signal non-stationarities—the method enabled extraction of satisfactory average COS waveforms, from which the system reliably captured positive and negative inotropic effects consistent with reference measurements during the pharmacological protocol. Significance: The evaluated algorithm demonstrates advancement over previous studies by enabling hemodynamic monitoring under usage conditions. Further studies are needed to extend its applicability to complex and physiologically relevant scenarios, positioning this technology as a potential non-invasive tool for preclinical research.
1 November 2026 in American Journal of Physiology-Heart and Circulatory Physiology
This study establishes a quantitative framework for hydrogen (H 2 ) pharmacokinetics, demonstrating that inhalation is the only way to achieve rapid and homogeneous systemic exposure, whereas hydrogen-rich water delivers H 2 only to downstream organs. Using complementary physiological, intragastric, and high-dose systemic approaches, we validate a nonsaturable pulmonary clearance model across clinically relevant and supraphysiological concentrations. These findings resolve inconsistencies in the literature and redefine how hydrogen-based therapies should be interpreted and optimized.